TIZIANA LIFE SCIENCES LTD (TLSA)
BMG889121031 - Common Stock
TLSA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. TLSA has a bad profitability rating. Also its financial health evaluation is rather negative. TLSA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year TLSA has reported negative net income.
In the past year TLSA has reported a negative cash flow from operations.
In the past 5 years TLSA always reported negative net income.
In the past 5 years TLSA always reported negative operating cash flow.
1.2 Ratios
TLSA has a Return On Assets of -126.31%. This is amonst the worse of the industry: TLSA underperforms 81.24% of its industry peers.
TLSA has a Return On Equity of -278.00%. This is in the lower half of the industry: TLSA underperforms 73.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -126.31% | ||
| ROE | -278% | ||
| ROIC | N/A |
ROA(3y)-83.77%
ROA(5y)-135.3%
ROE(3y)-151.66%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for TLSA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TLSA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TLSA has more shares outstanding
TLSA has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.44 indicates that TLSA is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.44, TLSA is in the better half of the industry, outperforming 74.69% of the companies in the same industry.
TLSA has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.02, TLSA perfoms like the industry average, outperforming 41.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.44 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
TLSA has a Current Ratio of 1.12. This is a normal value and indicates that TLSA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of TLSA (1.12) is worse than 86.55% of its industry peers.
TLSA has a Quick Ratio of 1.12. This is a normal value and indicates that TLSA is financially healthy and should not expect problems in meeting its short term obligations.
TLSA's Quick ratio of 1.12 is on the low side compared to the rest of the industry. TLSA is outperformed by 84.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 44.44% over the past year.
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-150%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
TLSA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.28% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.33%
EPS Next 2Y3.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
TLSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLSA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.28%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for TLSA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TIZIANA LIFE SCIENCES LTD
NASDAQ:TLSA (1/14/2025, 8:09:03 PM)
After market: 0.7198 -0.01 (-0.72%)0.725
-0.03 (-3.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.9%
Inst Owner Change0%
Ins Owners38.17%
Ins Owner ChangeN/A
Market Cap80.23M
Analysts82.86
Price Target3.06 (322.07%)
Short Float %0.95%
Short Ratio1.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 14.49 | ||
| P/tB | 14.49 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -126.31% | ||
| ROE | -278% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-83.77%
ROA(5y)-135.3%
ROE(3y)-151.66%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 2.44 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-150%
EPS Next Y13.33%
EPS Next 2Y3.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.99%
OCF growth 3YN/A
OCF growth 5YN/A